MKI67 and breast carcinoma: In the recent monarchE Phase 3 randomized trial, high levels of Ki-67 (≥20%) in patients with 1–3 positive nodes were used to select patients with high-risk ER+, HER2− breast cancer for ET with or without abemaciclib and inclusion in the study [13].